静脉用质子泵抑制剂使用合理性分析及院内管控  

Analysis of the reasonability of the use of intravenous proton pump inhibitors and its in-hospital control

作　　者：庞立峰[1] 华素[1] PANG Lifeng;HUA Su(Department of Pharmacy,Nanyang First People’s Hospital,Nanyang 473010,China)

机构地区：[1]南阳市第一人民医院药学部,南阳473010

出　　处：《上海医药》2024年第3期25-27,54,共4页Shanghai Medical & Pharmaceutical Journal

基　　金：南阳市科技攻关计划项目(KJGG007)。

摘　　要：目的:探讨我院静脉用质子泵抑制剂(PPIs)使用的合理性。方法:收集2022年度我院使用PPI的病例,共226份病历资料符合要求。结果:进入季度使用金额排名前五名次数最多的PPIs依次是注射用艾司奥美拉唑、注射用艾普拉唑、注射用雷贝拉唑、注射用奥美拉唑;病历不合理率为64.16%,无适应证用药53例(36.55%),用法用量不适宜46例(31.72%),疗程不适宜21例(14.48%),遴选药品不适宜17例(11.72%),联合用药不适宜5例(3.45%),溶媒不适宜3例(2.07%)。结论:对PPI使用不合理的现象需要加强重点品种管控,提升医师的合理用药水平,促进合理用药。Objective:To investigate the reasonability of the use of intravenous proton pump inhibitors(PPIs)in our hospital.Methods:The cases using PPIs in our hospital in 2022 were collected,and a total of 226 medical records met the requirements.Results:The PPI injections with the highest number of times listed in the top five quarterly amounts were in order esomeprazole,eprazole,rabeprazole and omeprazole.The unreasonable rate in the 226 medical records accounted for 64.16%,of which 53 cases(36.55%)were used without indications,46 cases(31.72%)were not suitable for dose,21 cases(14.48%)were not suitable for the course of treatment,and 17 cases were not suitable for drug selection(11.72%),5 cases(3.45%)were not suitable for combination,3 cases(2.07%)were not suitable for solvent.Conclusion:The phenomenon of unreasonable use of PPIs requires strengthening the control of key varieties and improving the level of rational medication among physicians so as to promote rational medication.

关 键 词：质子泵抑制剂 合理用药 管控 

分 类 号：R975.2[医药卫生—药品] R969.3[医药卫生—药学]